Feb 1, 2018 Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN(R)
Jan 29, 2018 Oncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market
Jan 19, 2018 Oncolytics Biotech(R) Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
Jan 16, 2018 Oncolytics Biotech® Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
Dec 27, 2017 Oncolytics Biotech® Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas
Dec 5, 2017 Oncolytics Biotech® Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN® in Metastatic Breast Cancer
Nov 30, 2017 Oncolytics Biotech® Establishes Scientific Advisory Board Focused on REOLYSIN® Registration Study in Metastatic Breast Cancer
Nov 16, 2017 Oncolytics Biotech® Inc. and Adlai Nortye Enter into USD $86.6 Million Regional Licensing Agreement for REOLYSIN®
